Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Emory University Celgene Corporation |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00209014 |
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.
Condition | Intervention | Phase |
---|---|---|
B-Cell Lymphoma Hodgkin's Disease |
Drug: Thalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease |
Estimated Enrollment: | 20 |
Study Start Date: | July 2003 |
Study Completion Date: | June 2006 |
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. This research is being done because current treatment does not help everyone with this disease. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma. Thalidomide has been shown to have activity against other cancers but is not approved by the FDA for treatment of lymphoma. Thalidomide prevents growth of new blood vessels that allow cancer cells to receive nourishment and spread. Another reason for doing the study is that researchers want to learn more about how the drug works and whether some patients respond better than others.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Georgia | |
Emory University Winship Cancer Institute | |
Atlanta, Georgia, United States, 30322 |
Principal Investigator: | L. Thompson Heffner, MD | Emory University Winship Cancer Institute |
Study ID Numbers: | 0544-2003 |
Study First Received: | September 13, 2005 |
Last Updated: | December 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00209014 |
Health Authority: | United States: Institutional Review Board |
B-Cell Lymphoma Hodgkin's Disease |
Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Hodgkin's disease Thalidomide Hodgkin lymphoma, adult Lymphoma, B-Cell Lymphoma, large-cell |
Lymphatic Diseases B-cell lymphomas Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma Hodgkin Disease |
Anti-Infective Agents Neoplasms by Histologic Type Immune System Diseases Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs Immunosuppressive Agents |
Angiogenesis Inhibitors Pharmacologic Actions Anti-Bacterial Agents Neoplasms Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Leprostatic Agents |